期刊
ACTA PHARMACEUTICA SINICA B
卷 12, 期 3, 页码 1126-1147出版社
INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2021.09.025
关键词
Biomimetic membrane; Nanomodulators; Immune system; Bioengineering; Immunotherapy; Autoimmune; Infectious diseases
资金
- Major State Basic Research Development Program of China [2017YFA0205201]
- National Natural Science Foundation of China [81925019, 81901876, 81801817, 81603015, U1705281]
- Fundamental Research Funds for the Central Universities (China) [20720190138, 20720190088, 20720200019]
- Medical and Health Key project of Xiamen (China) [3502Z20191106, 2020Y4003]
- Program for New Century Excellent Talents in University, China [NCET13-0502]
- China Postdoctoral Science Foundation Funded Project (China) [K6419001]
In this paper, recent advancements in bioinspired membrane-coated nanoplatform for systemic protection against immune-related diseases, including autoimmune and infectious diseases, are summarized. The challenges and limitations in the progress of therapeutic nanoplatform are also discussed, and the further application of nanomodulators in translational medicine for combating immune-related diseases is explored.
Autoimmune or infectious diseases often instigate the undesirable damages to tissues or organs to trigger immune-related diseases, which involve plenty of immune cells, pathogens and autoantibodies. Nanomedicine has a great potential in modulating immune system. Particularly, biomimetic nanomodulators can be designed for prevention, diagnosis and therapy to achieve a better targeted immunotherapy. With the development of materials science and bioengineering, a wide range of membranecoated nanomodulators are available. Herein, we summarize recent advancements of bioinspired membrane-coated nanoplatform for systemic protection against immune-related diseases including autoimmune and infectious diseases. We also rethink the challenges or limitations in the progress of the therapeutic nanoplatform, and discuss the further application of the nanomodulators in the view of translational medicine for combating immune-related diseases. (C) 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据